Complement inhibition in biomaterial- and biosurface-induced thromboinflammation. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Ekdahl, Kristina N.; Huang, Shan; Nilsson, Bo; Teramura, Yuji
• Is Part Of: Seminars in immunology. Volume 28:Issue 3(2016)
• Page Start: 268
• Page End: 277
• Publication Date: 2016-06
• Subjects: Biomaterials -- Coagulation -- Complement -- Inflammation -- Platelets -- Therapeutic medicine; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Immunity -- Periodicals; Immunologie -- Périodiques; Electronic journals; 616.079
• DOI: 10.1016/j.smim.2016.04.006
• Languages: English
• ISSNs: 1044-5323

Abstract

Highlights: Thromboinflammation is a major obstacle in modern therapeutic medicine. It is triggered both by biomaterials and cell surfaces in contact with blood. Thromboinflammation can be lowered by specific inhibitors bound to surfaces. This is a promising emerging strategy to improve clinical outcome. Abstract: Therapeutic medicine today includes a vast number of procedures involving the use of biomaterials, transplantation of therapeutic cells or cell clusters, as well as of solid organs. These treatment modalities are obviously of great benefit to the patient, but also present a great challenge to the innate immune system, since they involve direct exposure of non-biological materials, cells of non-hematological origin as well as endothelial cells, damaged by ischemia-perfusion in solid organs to proteins and cells in the blood. The result of such an exposure may be an inappropriate activation of the complement and contact/kallikrein systems, which produce mediators capable of triggering the platelets and PMNs and monocytes, which can ultimately result in thrombotic and inflammatory (i.e., a thrombo-inflammatory) response to the treatment modality. In this concept review, we give an overview of the mechanisms of recognition within the innate immunity system, with the aim to identify suitable points for intervention. Finally, we discuss emerging and promising techniques for surface modification of biomaterials and cells with specific inhibitors in order to diminish thromboinflammation and improve clinical outcome.